ArticleThe Journal of biological chemistry2019
Dihydronicotinamide riboside is a potent NAD
Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 112 citations in OpenAlex.
- Peripheral Neuropathy in Metabolic Stress.International journal of molecular sciences · 2026Review
- Astrocytic Redox Homeostasis as a Metabolic Modulator of DNA Damage and Repair in the Ischemic Penumbra.Cells · 2026Review
- Formate Dehydrogenase: The Role of the AMP Cofactor Fragment in Stabilization of the Transition State for Enzyme-Catalyzed Hydride Transfer.ACS omega · 2026Article
- Therapeutic potential of dihydronicotinamide riboside (NRH) on obesity and glucose intolerance in mice.Nature communications · 2026Article
- Reduced Versus Oxidized NADFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Differential regulation of SIRT5 activity by reduced nicotinic acid riboside (NARH).RSC chemical biology · 2026Article
- Enzyme Architecture: Activation of Phosphite Dehydrogenase-Catalyzed Hydride Transfer by NADBiochemistry · 2025Article
- Emerging strategies, applications and challenges of targeting NADNature aging · 2025Review
- The role of NADnpj metabolic health and disease · 2025Review
- NADAtherosclerosis · 2025Article
- Insights into the cellular function and mechanism of action of quinone reductase 2 (NQO2).The Biochemical journal · 2025Review
- NRH, a potent NADMetabolism: clinical and experimental · 2025Article
- NAD+ Boosting Through NRH Supplementation Enhances Treatment Efficacy in EOC In Vitro.International journal of molecular sciences · 2025Article
- Evolutionary analysis of Quinone Reductases 1 and 2 suggests that NQO2 evolved to function as a pseudoenzyme.Protein science : a publication of the Protein Society · 2024Article
- NADCell communication and signaling : CCS · 2024Review
- Glycerol 3-Phosphate Dehydrogenase Catalyzed Hydride Transfer: Enzyme Activation by Cofactor Pieces.Biochemistry · 2024Article
- Regulation of and challenges in targeting NADNature reviews. Molecular cell biology · 2024Review
- Nicotinamide Adenine Dinucleotide Precursor Supplementation Modulates Neurite Complexity and Survival in Motor Neurons from Amyotrophic Lateral Sclerosis Models.Antioxidants & redox signaling · 2024Article
- Chemical tools for profiling the intracellular ADP-ribosylated proteome.RSC chemical biology · 2024Article
- Nicotinamide Mononucleotide Supplementation: Understanding Metabolic Variability and Clinical Implications.Metabolites · 2024Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Interest in pharmacological agents capable of increasing cellular NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.